NovaBay Pharmaceuticals, Inc. (NBY) Financials
NBY Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2024-03-31 | 5.4 million | 5.2 million |
| 2023-12-31 | 9.0 million | 5.7 million |
| 2023-09-30 | 12.9 million | 5.8 million |
| 2023-06-30 | 16.0 million | 7.4 million |
NBY Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2024-03-31 | -1.6 million | 60000 |
| 2023-12-31 | -203000 | 90000 |
| 2023-09-30 | -365000 | 62000 |
| 2023-06-30 | -1.8 million | 64000 |
NBY Net Income
No data available :(
NBY Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2024-03-31 | 1.8 million | - | - |
| 2023-12-31 | 3.1 million | - | 1.6 million |
| 2023-09-30 | 3.5 million | - | 1.7 million |
| 2023-06-30 | 4.4 million | - | 1.9 million |
NBY Shares Outstanding
NBY Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2024-03-31 | 2000 | 19000 | 2.3 million | 1.1 million |
| 2023-12-31 | 2000 | 4000 | 1.2 million | 1.4 million |
| 2023-09-30 | 2000 | 11000 | 1.2 million | 1.7 million |
| 2023-06-30 | 2000 | 27000 | 1.9 million | 1.7 million |
NBY Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2024-03-31 | 2.6 million | 837000 |
| 2023-12-31 | 3.7 million | 1.9 million |
| 2023-09-30 | 3.3 million | 1.4 million |
| 2023-06-30 | 4.6 million | 2.3 million |
NBY
Price: $0.21
52 week price:
Earnings Per Share: -3.96 USD
P/E Ratio: -0.02
Exchange: ASE
Sector: Healthcare
Industry: Biotechnology
Volume: 100900
Market Capitalization: 4.5 million